



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Teizo Yoshimura et al

Serial No.: 07/330,446

Group: 185

Filed : March 30, 1989

Examiner: Dian Cook

For : HUMAN DERIVED MONOCYTE ATTRACTING PURIFIED PROTEIN
PRODUCT USEFUL IN A METHOD OF TREATING INFECTION AND
NEOPLASMS IN A HUMAN BODY, AND THE CLONING OF FULL
LENGTH cDNA THEREOF

A M E N D M E N T

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

November 15, 1991

Sir:

In response to the Office Action dated May 15, 1991, the due date for response having been extended to November 15, 1991, the following remarks and amendments are respectfully submitted herewith in connection with the above-identified application.

IN THE SPECIFICATION

Page 8

Please insert the following paragraph between lines 10 and 11:

"The term "LAMBDA ZAP II®" as used herein refers to a commercially available general purpose lambda cloning vector with automatic *in vivo* excision of plasmids subclones containing as cloning sites EcoR I, Not I, Xba I, Spe I, Xho I and Sac I, and which is capable of accepting an insert with a size of 0 to 10 Kb.

LAMBDA ZAP II® is commercially available from STRATAGENE, 11099

North Torrey Pines Road, La Jolla, California 92037."